Why the study?
CKD and type 2 diabetes are associated with heart failure; these prespecified FIGARO-DKD analyses assessed the effect of finerenone on clinically important HF outcomes.
Does finerenone reduce new-onset heart failure and other heart failure outcomes in patients with chronic kidney disease and type 2 diabetes?
Population
7352 patients with type 2 diabetes and albuminuric CKD without symptomatic HFrEF
Comparison
Finerenone vs placebo
Design
Prespecified randomized controlled trial analysis
Key result
Finerenone significantly reduced the risk of new-onset heart failure compared to placebo (1.9% vs 2.8%; HR 0.68; 95% CI 0.50-0.93; P=0.0162) in patients with CKD and type 2 diabetes.
Loading...
Supports finerenone for incident HF prevention in CKD with T2D; extends prior cardiorenal benefits to HF outcomes.
RCT (n=7,352)
randomized
Does finerenone reduce new-onset heart failure and other heart failure outcomes in patients with chronic kidney disease and type 2 diabetes?
Hazard Ratio: 0.68 (95% CI 0.5–0.93)
Absolute Event Rate: 1.9% vs 2.8%
p-value: p=0.0162
Finerenone significantly reduces the risk of incident heart failure and improves overall heart failure outcomes in patients with type 2 diabetes and albuminuric chronic kidney disease.
A 2021 study conducted an RCT in chronic kidney disease and type 2 diabetes (n=7,352). Finerenone vs. placebo was evaluated on new-onset HF (HR 0.68, 95% CI 0.50-0.93, p=0.0162). Finerenone significantly reduced the risk of new-onset heart failure compared to placebo (1.9% vs 2.8%; HR 0.68; 95% CI 0.50-0.93; P=0.0162) in patients with CKD and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: